CTRI/2017/11/010560已完成2 期
An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared with Insulin Aspart in the Treatment of Patients with Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Key Inclusion Criteria:
- •1.Patients with an established diagnosis of T2DM and a duration of diabetes mellitus of at least 6 months at Screening based on criteria given below as per American Diabetes Association (ADA) 2017 guidelines:
- •i. HbA1c >= 6.5% OR
- •ii. FPG >= 126 mg/dL. (Fasting is defined as no caloric intake for at least 8 hours.) OR
- •iii.2-hour prandial glucose (PG) level of >= 200 mg/dL during an oral glucose tolerance test (OGTT). The test should be performed as described by the World Health Organisation (WHO), using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. OR
- •iv.In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >= 200 mg/dL.
- •(If there is suspicion, the investigator can do a fasting plasma C-peptide [Levels < 0.3 nmol/L is indicative of Type 1 Diabetes Mellitus (T1DM) and would need the patient to be excluded]).
- •2.Stable dose of metformin (at least 1500 mg daily [daily dose of at least 1000 mg is permitted if intolerant to 1500 mg dose]) for a period of at least 3 months prior to Screening
- •3.Eligible for initiation of or already receiving insulin glargine
- •4.Hemoglobin >= 10.0 g/dL
- •5.HbA1c of 7.5% to 10.0 %
- •6.Body mass index of 18.5 to 35.0 kg/m2
排除标准
- •Key Exclusion Criteria:
- •1.Patients with T1DM
- •2.Treatment with glucagon-like peptide 1 agonists within 12 weeks prior to Screening
- •3.Ongoing treatment with OADs (eg, Thiazolidinediones) contraindicated or unapproved for combination treatment with insulin
- •4.Presence of gastrointestinal (GI) disorders or conditions known to significantly alter the absorption of orally administered drugs or significantly alter upper GI or pancreatic function
- •5.History of >=2 episodes of severe hypoglycemia (as per ADA 2017) within the 6 months before Screening
- •6.History of > 1 episode of hyperglycemic hyperosmolar coma or hospitalization for uncontrolled diabetes (eg, diabetic ketoacidosis); within the 6 months prior to Screening
- •7.Clinically significant cardiovascular and/or cerebrovascular disease within 12 months before Screening including, but not limited to unstable angina, myocardial infarction, Class III or Class IV congestive heart failure according to the New York Heart Association criteria, valvular heart disease, cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke or transient ischemic attack.
- •8.Patients with the following secondary complications of diabetes:
- •i.Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy (by the investigator, site ophthalmologist or an optometrist; as per standard site practice) within 6 months prior to Screening.
- •ii.Renal dysfunction indicated by modification of diet in renal disease estimated glomerular filtration rate < 45 mL/min/1.73 m2 and/or diabetic nephropathy and/or clinical nephrotic syndrome at Screening.
- •iii.History or presence of severe form of neuropathy or signs and symptoms of severe cardiac autonomic neuropathy.
- •iv.Patients with non-traumatic amputation (at any time) or clinically significant vascular procedure as a complication of diabetes within 1 year prior to Screening.
- •v.History of diabetic foot ulcer or non-healing diabetic ulcers in the 1 year prior to Screening
研究者
相似试验
进行中（未招募）
不适用
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 2 Diabetes MellitusEUCTR2006-006600-11-DEBIODEL Inc.400
进行中（未招募）
不适用
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes MellitusDiabetes Mellitus Type 1MedDRA version: 8.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2006-006599-39-DEBIODEL Inc.400
进行中（未招募）
1 期
A clinical study to compare brincidofovir with current care for adenovirus infection in children after a bone marrow transplantEUCTR2017-001735-39-DEChimerix, Inc141
撤回
2 期
An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant RecipientsAdenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients10047438NL-OMON46433Chimerix, Inc.10
进行中（未招募）
1 期
A clinical study to compare brincidofovir with current care for adenovirus infection in children after a bone marrow transplantTreatment of adenovirus infections in high-risk pediatric allogeneic allogenic hematopoietic cell transplant recipientsMedDRA version: 20.1Level: PTClassification code 10060931Term: Adenovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001735-39-GBChimerix, Inc29